Emma Duffield
About
Emma Duffield is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Emma Duffield has authored 21 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Surgery. Recurrent topics in Emma Duffield's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Research Studies (8 papers). Emma Duffield is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Research Studies (8 papers). Emma Duffield collaborates with scholars based in United Kingdom, Hong Kong and Japan. Emma Duffield's co-authors include Alison Armour, Nagahiro Saijo, Tony Mok, Masahiro Fukuoka, Haiyi Jiang, James Chih‐Hsin Yang, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong and Yuichiro Ohe and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The American Journal of Cardiology.
In The Last Decade
Emma Duffield
21 papers receiving 8.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Emma Duffield United Kingdom | 13 | 7.2k | 5.7k | 2.1k | 2.1k | 528 | 21 | 8.5k | ||
| Patrapim Sunpaweravong Thailand | 16 | 7.1k 1.0× | 5.7k 1.0× | 2.2k 1.1× | 1.9k 0.9× | 579 1.1× | 57 | 8.5k | ||
| Claire Watkins United Kingdom | 21 | 7.8k 1.1× | 7.5k 1.3× | 2.9k 1.4× | 2.1k 1.0× | 660 1.3× | 42 | 11.0k | ||
| Jin-Ji Yang China | 10 | 6.6k 0.9× | 5.1k 0.9× | 2.0k 1.0× | 1.8k 0.9× | 348 0.7× | 12 | 7.6k | ||
| José Rodrigues Pereira Brazil | 17 | 7.0k 1.0× | 6.3k 1.1× | 2.0k 1.0× | 1.2k 0.6× | 601 1.1× | 25 | 8.7k | ||
| В. А. Горбунова Russia | 24 | 5.5k 0.8× | 4.5k 0.8× | 2.3k 1.1× | 1.4k 0.7× | 956 1.8× | 61 | 7.2k | ||
| Benjamin Margono Indonesia | 4 | 5.8k 0.8× | 4.5k 0.8× | 1.7k 0.8× | 1.8k 0.9× | 290 0.5× | 6 | 6.8k | ||
| Haiyi Jiang Japan | 24 | 8.2k 1.1× | 6.8k 1.2× | 2.4k 1.2× | 2.1k 1.0× | 504 1.0× | 53 | 9.9k | ||
| Chun‐Ming Tsai Taiwan | 31 | 6.4k 0.9× | 5.3k 0.9× | 2.0k 1.0× | 1.4k 0.7× | 417 0.8× | 114 | 7.8k | ||
| Busyamas Chewaskulyong Thailand | 7 | 5.5k 0.8× | 4.3k 0.8× | 1.7k 0.8× | 1.5k 0.7× | 302 0.6× | 20 | 6.5k | ||
| Baohui Han China | 8 | 5.5k 0.8× | 4.3k 0.8× | 1.7k 0.8× | 1.5k 0.7× | 302 0.6× | 10 | 6.5k |
Countries citing papers authored by Emma Duffield
Since
Specialization
Citations
This map shows the geographic impact of Emma Duffield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Duffield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Duffield more than expected).
Fields of papers citing papers by Emma Duffield
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Emma Duffield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Duffield. The network helps show where Emma Duffield may publish in the future.
Co-authorship network of co-authors of Emma Duffield
This figure shows the co-authorship network connecting the top 25 collaborators of Emma Duffield. A scholar is included among the top collaborators of Emma Duffield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Duffield. Emma Duffield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gettinger, Scott, Sarah B. Goldberg, Anne C. Chiang, et al.. (2023). MA15.07 NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC. Journal of Thoracic Oncology. 18(11). S155–S155.
2.
Spindler, Alberto, Juan J. Gómez‐Reino, Edward J. Fudman, et al.. (2013). Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist. Data Archiving and Networked Services (DANS).
3.
Wu, Yi‐Long, Baohui Han, Xuyi Liu, et al.. (2012). Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pacific Journal of Clinical Oncology. 8(3). 232–243.
4.
Thongprasert, Sumitra, Emma Duffield, Nagahiro Saijo, et al.. (2011). Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). Journal of Thoracic Oncology. 6(11). 1872–1880.
5.
Goto, Kōichi, Yukito Ichinose, Yuichiro Ohe, et al.. (2011). Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(1). 115–121.
6.
Wu, Yi‐Long, N. Saijo, Sumitra Thongprasert, et al.. (2011). 9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS. European Journal of Cancer. 47. S633–S633.
7.
Fukuoka, Masahiro, Yi‐Long Wu, Sumitra Thongprasert, et al.. (2011). Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS). Journal of Clinical Oncology. 29(21). 2866–2874.
8.
Mok, Tony, Yi‐Long Wu, Sumitra Thongprasert, et al.. (2009). Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine. 361(10). 947–957.
9.
Yamamoto, Nobuyuki, Y. Ichinose, Yutaka Nishiwaki, et al.. (2009). OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC). European Journal of Cancer Supplements. 7(4). 10–10.
10.
Wu, Yi‐Long, Tony Mok, D. Chu, et al.. (2009). Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Journal of Clinical Oncology. 27(15_suppl). 8041–8041.
11.
Ichinose, Y., Yutaka Nishiwaki, Norio Yamamoto, et al.. (2009). Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan. Journal of Clinical Oncology. 27(15_suppl). 8044–8044.
12.
Goss, Glenwood, David Ferry, Rafal Wierzbicki, et al.. (2009). Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status. Journal of Clinical Oncology. 27(13). 2253–2260.
13.
Færgeman, Ole, et al.. (2008). Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia. Cardiology. 111(4). 219–228.
14.
Crinò, Lucio, Federico Cappuzzo, Petr Zatloukal, et al.. (2008). Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. Journal of Clinical Oncology. 26(26). 4253–4260.
15.
Crinò, Lucio, Petr Zatloukal, Martin Reck, et al.. (2007). B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study. Journal of Thoracic Oncology. 2(8). S341–S341.
16.
Fennell, Michael, Vivien N. Jacobs, Francesco Pinto, et al.. (2007). The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemotherapy and Pharmacology. 61(1). 23–32.
17.
Ballantyne, Christie M., Robert Weiss, Tiziano Moccetti, et al.. (2007). Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). The American Journal of Cardiology. 99(5). 673–680.
18.
Goss, Glenwood, David Ferry, Scott A. Laurie, et al.. (2007). B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP). Journal of Thoracic Oncology. 2(8). S340–S340.
19.
Duffield, Emma, et al.. (2006). Th-P16:270 Efficacy and safety of rosuvastatin plus ezetimibe in high-risk patients: Results from the explorer study. Atherosclerosis Supplements. 7(3). 552–552.
20.
Færgeman, Ole, et al.. (2006). Th-P16:394 Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in high-risk patients: Results from the eclipse study. Atherosclerosis Supplements. 7(3). 580–580.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Patrapim Sunpaweravong Breakdown of academic impact, for papers by Claire Watkins Breakdown of academic impact, for papers by Jin-Ji Yang Breakdown of academic impact, for papers by José Rodrigues Pereira Breakdown of academic impact, for papers by В. А. Горбунова Breakdown of academic impact, for papers by Benjamin Margono Breakdown of academic impact, for papers by Haiyi Jiang Breakdown of academic impact, for papers by Chun‐Ming Tsai Breakdown of academic impact, for papers by Busyamas Chewaskulyong Breakdown of academic impact, for papers by Baohui Han